Arcus Biosciences' (RCUS) Research Engine Continues to be Productive, Management Executes on Clinical Strategy - Truist
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $70.00 price target on Arcus Biosciences (NYSE: RCUS), following recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
